LIVE February 27: Round table debate on longevity and compliance in cell and gene therapies
Join our panel of multidisciplinary experts as they consider the longevity and compliance of cell and gene therapies. As part of this Accelerating Science Feature, SelectScience® will bring together experts and industry leaders in cell and gene therapy research, manufacturing, and compliance to discuss the first-ever approval of a gene-editing-based therapy Casgevy.
Register for your free place here
Bioprocessing solutions optimize therapy workflows
In this eBook, explore bioprocessing methods for the large-scale cultivation and production of a variety of stem cells.
Non-viral transposon versus lentiviral delivery
Learn about how a novel non-viral gene delivery system that could transform cell and gene therapy workflows.
mRNA manufacturing to boost therapy and vaccine output
mRNA-based therapies and vaccines could be developed more quickly and cheaply thanks to a new manufacturing unit at the University of Sheffield.
Experts explore new trends in cell and gene therapy
Discover the latest techniques and methods that are helping to make cell and gene therapies the future of medicine.
Optimize AAV capsid purification using mass photometry
Find out how viral vector experts accelerate their AAV capsid purification using mass photometry.
AAV aggregate quantitation and identification
Learn how you can explore AAV stability and subvisible aggregates using as low as 10 μL per sample.
Empowering advancement across cell and gene therapy
Advancements in the field of human genomics, transcriptomics, and proteomics have given rise to high-throughput, affordable, and potentially life-changing cell and gene therapies to treat individuals with genetic diseases. Explore our feature to gain expert insights into:
Accelerating Science Forum: Longevity and compliance in cell and gene therapies
Join our panel of multidisciplinary experts as they consider the longevity and compliance of cell and gene therapies.
As part of this Accelerating Science Feature, SelectScience® will bring together experts and industry leaders in cell and gene therapy research, manufacturing, and compliance to discuss the first-ever approval of a gene-editing-based therapy Casgevy.
Exploring the potential of other innovative cell and gene therapy types alongside this critical approval, key topics such as monitoring long-term efficacy, identifying potential risks, improving manufacturing processes, optimizing dosing regimens, and developing robust monitoring systems, will also be discussed.
Whether you are a researcher, healthcare professional, industry representative, or simply interested in the future of medicine, this event will equip you with valuable knowledge and understanding of the challenges and potential solutions related to the longevity and compliance of cell and gene therapies.
Key learning objectives
Register for your free place here
- Discuss the first-ever approval of gene-editing-based therapy Casgevy for sickle cell disease.
- Explore the challenges and advancements in ensuring the safety and long-term therapeutic effects of cell and gene therapies.
- Examine the complexities involved in researching, developing and producing these treatments, and the types of solutions available.
- Discuss the hurdles faced in achieving regulatory compliance for cell and gene therapies.
Share your story, scientific knowledge, and accelerate science by becoming a SelectScience member.
Join for free today
A special thank you to all our sponsors of this feature. If you'd like to be involved, please
*Certain images and/or photos on this page are the copyrighted property of 123RF.com or Adobe Stock, its contributors or its licensed partners and are being used with permission under the relevant license. These images and/or photos may not be copied or downloaded without permission from 123RF.com or Adobe Stock.